

## Medical drug benefit *Clinical Criteria* updates

**Summary:** On August 16, 2019, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Amerigroup. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (\*): Criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

**Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical plan. This does not apply to pharmacy services.**

Effective date	Document number	<i>Clinical Criteria</i> title	New, revised, annual review
November 30, 2019	ING-CC-0142	<i>Somatuline Depot (lanreotide)*</i>	New
November 30, 2019	ING-CC-0143	<i>Polivy (polatuzumab vedotin-piiq)*</i>	New
November 30, 2019	ING-CC-0144	<i>Lumoxiti (moxetumomab pasudotox-tdfk)*</i>	New
November 30, 2019	ING-CC-0145	<i>Libtayo (cemiplimab-rwlc)*</i>	New
November 30, 2019	ING-CC-0030	<i>Implantable and ER Buprenorphine Containing Agents</i>	Revised
November 30, 2019	ING-CC-0036	<i>Naltrexone Implantable Pellets</i>	Reviewed
November 30, 2019	ING-CC-0002	<i>Colony Stimulating Factor Agents*</i>	Revised
November 30, 2019	ING-CC-0001	<i>Erythropoiesis Stimulating Agents*</i>	Revised
November 30, 2019	ING-CC-0107	<i>Bevacizumab for Non-Ophthalmologic Indications*</i>	Revised
November 30, 2019	ING-CC-0114	<i>Jevtana (cabazitaxel)</i>	Revised
November 30, 2019	ING-CC-0134	<i>Provence (sipuleucel-T)</i>	Revised
November 30, 2019	ING-CC-0127	<i>Darzalex (daratumumab)</i>	Revised
November 30, 2019	ING-CC-0106	<i>Erbix (cetuximab)*</i>	Revised
November 30, 2019	ING-CC-0105	<i>Vectibix (panitumumab)</i>	Revised
November 30, 2019	ING-CC-0124	<i>Keytruda (pembrolizumab)</i>	Revised
November 30, 2019	ING-CC-0128	<i>Tecentriq (atezolizumab)</i>	Revised
November 30, 2019	ING-CC-0104	<i>Levoleucovorin Agents</i>	Reviewed
November 30, 2019	ING-CC-0125	<i>Opdivo (nivolumab)</i>	Revised

Amerigroup members in the Medicaid Rural Service Area and the STAR Kids program are served by Amerigroup Insurance Company; all other Amerigroup members in Texas are served by Amerigroup Texas, Inc.

Coverage provided by Amerigroup Inc.

Effective date	Document number	Clinical Criteria title	New, revised, annual review
November 30, 2019	ING-CC-0129	<i>Bavencio (avelumab)</i>	Revised
November 30, 2019	ING-CC-0130	<i>Imfinzi (durvalumab)</i>	Revised
November 30, 2019	ING-CC-0119	<i>Yervoy (ipilimumab)</i>	Revised
November 30, 2019	ING-CC-0094	<i>Alimta (pemetrexed disodium)</i>	Revised
November 30, 2019	ING-CC-0099	<i>Abraxane (paclitaxel, protein bound)</i>	Revised
November 30, 2019	ING-CC-0048	<i>Spinraza (nusinersen)*</i>	Revised
November 30, 2019	ING-CC-0010	<i>Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors</i>	Revised
November 30, 2019	ING-CC-0034	<i>Hereditary Angioedema Agents*</i>	Revised
November 30, 2019	ING-CC-0014	<i>Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis</i>	Revised
November 30, 2019	ING-CC-0020	<i>Tysabri (natalizumab)</i>	Revised
November 30, 2019	ING-CC-0011	<i>Ocrevus (ocrelizumab)</i>	Revised
November 30, 2019	ING-CC-0075	<i>Rituximab Agents for Non-Oncology Indications*</i>	Revised
November 30, 2019	ING-CC-0009	<i>Lemtrada (alemtuzumab)</i>	Revised
November 30, 2019	ING-CC-0004	<i>H.P. Acthar Gel (repository corticotropin injection)</i>	Revised
November 30, 2019	ING-CC-0041	<i>Complement Inhibitors*</i>	Revised
November 30, 2019	ING-CC-0072	<i>Selective Vascular Endothelial Growth Factor (VEGF) Antagonists*</i>	Revised
November 30, 2019	ING-CC-0029	<i>Dupixent (dupilumab)</i>	Revised
November 30, 2019	ING-CC-0026	<i>Testosterone Injectable</i>	Revised
November 30, 2019	ING-CC-0008	<i>Subcutaneous Hormonal Implants</i>	Revised
November 30, 2019	ING-CC-0044	<i>Exondys 51 (eteplirsen)</i>	Reviewed
November 30, 2019	ING-CC-0028	<i>Benlysta (belimumab)</i>	Revised
November 30, 2019	ING-CC-0027	<i>Denosumab Agents</i>	Revised
November 30, 2019	ING-CC-0139	<i>Evenity (romosozumab-aqqg)</i>	Revised
November 30, 2019	ING-CC-0038	<i>Human Parathyroid Hormone Agents</i>	Revised
November 30, 2019	ING-CC-0019	<i>Zoledronic Acid Agents</i>	Revised
November 30, 2019	ING-CC-0082	<i>Onpattro (patisiran)*</i>	Revised
November 30, 2019	ING-CC-0031	<i>Intravitreal Corticosteroid Implants*</i>	Revised
November 30, 2019	ING-CC-0084	<i>Tegsedi (inotersen)*</i>	Revised
November 30, 2019	ING-CC-0025	<i>Aldurazyme (laronidase)*</i>	Revised
November 30, 2019	ING-CC-0073	<i>Alpha-1 Proteinase Inhibitor Therapy*</i>	Revised
November 30, 2019	ING-CC-0032	<i>Botulinum Toxin*</i>	Revised
November 30, 2019	ING-CC-0024	<i>Elaprase (idursufase)*</i>	Revised
November 30, 2019	ING-CC-0071	<i>Entyvio (vedolizumab)*</i>	Revised
November 30, 2019	ING-CC-0051	<i>Enzyme Replacement Therapy for Gaucher Disease*</i>	Revised
November 30, 2019	ING-CC-0021	<i>Fabrazyme (agalsidase beta)*</i>	Revised
November 30, 2019	ING-CC-0061	<i>GnRH Analogs for the treatment of Non-Oncologic indications*</i>	Revised
November 30, 2019	ING-CC-0003	<i>Immunoglobulins*</i>	Revised

<b>Effective date</b>	<b>Document number</b>	<b>Clinical Criteria title</b>	<b>New, revised, annual review</b>
November 30, 2019	ING-CC-0018	<i>Lumizyme (alglucosidase alfa)*</i>	Revised
November 30, 2019	ING-CC-0013	<i>Mepsevii (vestronidase alfa)*</i>	Revised
November 30, 2019	ING-CC-0050	<i>Monoclonal Antibodies to Interleukin-23*</i>	Revised
November 30, 2019	ING-CC-0043	<i>Monoclonal Antibodies to Interleukin-5*</i>	Revised
November 30, 2019	ING-CC-0066	<i>Monoclonal Antibodies to Interleukin-6*</i>	Revised
November 30, 2019	ING-CC-0023	<i>Naglazyme (galsulfase)*</i>	Revised
November 30, 2019	ING-CC-0058	<i>Octreotide Agents*</i>	Revised
November 30, 2019	ING-CC-0063	<i>Stelara (ustekinumab)*</i>	Revised
November 30, 2019	ING-CC-0007	<i>Synagis (palivizumab)*</i>	Revised
November 30, 2019	ING-CC-0062	<i>Tumor Necrosis Factor Antagonists*</i>	Revised
November 30, 2019	ING-CC-0022	<i>Vimizim (elosulfase alfa)*</i>	Reviewed
November 30, 2019	ING-CC-0033	<i>Xolair (omalizumab)*</i>	Reviewed